NuProbe Technology Showcases Quantitative PCR for

Houston, January 18, 2022 (GLOBE NEWSWIRE) – NuProbe, a genomics and molecular diagnostics company that develops ultra-sensitive tests for precision cancer research, today released research demonstrating new technology to qualitatively and quantitatively detect multiple low-grade variants frequency in a quantitative PCR (qPCR reaction). The new allele-specific BDA technology (As-BDA) uses qPCR to detect mutations up to 0.01% variant allele fraction (VAF) within 2 hours.

Blocker Displacement Amplification (BDA), one of NuProbe’s core technologies, removes wild type sequences from the library and selectively enriches rare variants, reaching a limit of detection (LoD) of 0.1% VAF in real-time PCR multiplexing and NGS. With standard BDA and real-time PCR, mutations within the enrichment region of the blocker can be identified with multiple reactions or another sequencing technology such as Sanger sequencing. As-BDA improves BDA by accurately reporting specific mutations within a sample at an improved detection limit.

Read more about BDA.

“Because BDA pushes the boundaries of current technologies, such as NGS and droplet digital PCR, in terms of sensitivity, multiplexity and simplicity of the workflow,” says Kerou Zhang, NuProbe consultant scientist and lead author of the research. “As-BDA identifies variants with high sensitivity and specificity, which makes it advantageous and potential in non-invasive profiling of mutations with liquid biopsy for cancer diagnosis and monitoring, where the VAF of the mutation is usually very low.”

The studies were conducted on a three-tube IDH2 assay and a single-tube assay of IDH2 R140Q. For the three tube assay, each tube detected up to 4 mutations simultaneously with a minimum VAF of 0.1% using a DNA input of 15 ng. Scientists also completed ddPCR comparison studies for the R140Q mutation using peripheral blood mononuclear cell (PMBC) DNA from 11 acute myeloid leukemia (AML) clinical samples, 7 healthy donor samples, and reference samples. The As-BDA results were 100% concordant with ddPCR for mutations as low as 0.1% VAF.

“We are excited about this new technology that can provide simultaneous qualitative and quantitative mutation detection with fast response time,” said David Zhang, NuProbe CEO and corresponding author of the research. “When translated into molecular diagnostics and genomic research, this technology has the potential to improve clinical sensitivity with rapid response times.”

About NuProbe

NuProbe is a pioneering molecular diagnostics and genomics company with breakthrough molecular diagnostic technologies to improve the sensitivity of sequencing mutations and copy number changes by more than 10-fold. NuProbe has offices in Houston, USA, Shanghai, China and Suzhou, China. NuProbe’s vision is to provide convenient, timely and accurate disease status information to enable precision medicine and improve patient outcomes.

NuProbe products are for research use only and are not intended for in vitro diagnostic use.

.

Read more here: Source link